Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer

NCT01573338 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01573338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01573338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Terminated
Start date
February 25, 2013
Completion date
June 23, 2016
Enrollment
43 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma